A case report on Aspergillus fumigatus causing pulmonary aspergillosis in an immunocompromised patient presenting as chronic obstructive pulmonary disease and pulmonary tuberculosis
DOI:
https://doi.org/10.18203/2394-6040.ijcmph20261442Keywords:
Pulmonary aspergillosis, Aspergillus fumigatus, HIV, VoriconazoleAbstract
Pulmonary aspergillosis (PA) is a complicated fungal infection caused by aspergillus species, predominantly affecting immunocompromised individuals. This case highlights the diagnostic complexities as it often mimics other respiratory diseases like tuberculosis (TB) and chronic obstructive pulmonary disease (COPD) and in a patient with advanced HIV. Case presentation: A 48-year-old male with HIV (on third-line antiretroviral therapy, CD4 count 150 cells/μL) presented with a one-week history of cough, wheezing, shortness of breath, and fatigue. Initial management for COPD and bacterial infection provided minimal relief. Extensive diagnostic workup, revealed elevated Aspergillus-specific IgG antibodies (122 U/ml) and IgE levels (67.60 KUA/l). High-resolution computed tomography (HRCT) of the chest revealed bilateral bronchiectasis, suggestive of fungal infection, confirming PA. Conclusion: This case underscores the importance of considering opportunistic fungal infections like PA in immunocompromised patients with non-resolving respiratory symptoms, even when classic radiological signs are absent or overlap with other pulmonary conditions.
References
Kousha M, Tadi R, Soubani AO. Pulmonary aspergillosis: a clinical review. European respiratory review. 2011;20(121):156-74.
Ao W, Huang P, Wang J, Fu X, Fu B. Fatal invasive pulmonary aspergillosis in non-immunocompromised host: A case report. Medicine. 2023;102(43): e35702.
National AIDS Control Organization. National AIDS Control Organization | MoHFW | GoI. 2017. Available at: https://naco.gov.in/. Accessed on 15 March 2026.
Kakamad FH, Mahmood SO, Rahim HM, Abdulla BA, Abdullah HO, Othman S, Mohammed SH, Kakamad SH, Mustafa SM, Salih AM. Post covid-19 invasive pulmonary Aspergillosis: a case report. Int J Surg Case Rep. 2021;82:105865.
Lamoth F, Calandra T. Pulmonary aspergillosis: diagnosis and treatment. Eur Respir Rev. 2022;31(166):220114.
Guziejko K, Klukowska K, Budzińska U, Mróz RM. Case Report: Chronic Pulmonary Aspergillosis-An Unusual Long-Term Complication of Lung Cancer Treatment. Frontiers in medicine. 2022;8:777457.
Naaraayan A, Kavian R, Lederman J, Basak P, Jesmajian S. Invasive pulmonary aspergillosis–case report and review of literature. J Comm Hospital Internal Med Perspectives. 2015;5(1):26322.
Herbrecht R, Denning DW, Patterson TF. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347:408-15.
Rathbun RC, Hoffman HL. Review of the safety and efficacy of voriconazole. Expert Opinion on Investigational Drugs. 2002;11(3):409-29.
Tingting C, Zhiqiang L, Huatang Z. Therapeutic Drug Monitoring of Voriconazole in AIDS Patiezts. Research Square. 2021.